Table 1.
Overview of patient characteristics.
| Fungal Infection | Sex, Age (y), Weight (kg) | Hematologic Disease | ISA Initial DoseRoute |
Co-Antifungal | Drugs Metabolized by CYP3A4 | Time to First ISA Level (days) | First ISA Ctrough (mg/L) | Capsules Opened at Any Time | Total Days of ISA | Median ISA Ctrough (mg/L) | Modification of Dosage | Balanced Dosage mg/day |
IFI Response at Day 15 | IFI Response at Day 90 | AST Spike (UI/L) | ALT Spike (UI/L) | Scr h Spike (µM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proven mucor a | F 5.4 y 20 kg | ALCL c | 100 mg IV | L-AmB e | lorlatinib | 5 | 1.77 | NO | 105 | 2.14 | Increased, 2 times | 200 | partial | complete | 33 | 15 | 72 |
| Proven mucor a | M 6.5 y 19 kg | B-ALL | 100 mg IV | L-AmB e | NA | 3 | 2.77 | NO | 64 | 2.58 | Increased, 3 times | 200 | stable | partial | 269 | 339 | 42 |
| Proven mucor a | M 2.4 y 13 kg | B-ALL | 100 mg Oral | L-AmB e | NA | 9 | 1.6 | YES | 276 | 2.30 | Increased, 1 time | 130 | stable | complete | 34 | 22 | 55 |
| Proven Asp b flavus | F 10.9 y 30 kg | T-ALL | 100 mg IV | CASP f | CsA g | 8 | 0.73 | NO | 356 | 3.22 | Increased, 1 time | 200 | stable | complete | 59 | 83 | 29 |
| Probable Asp b fumigatus | F 2.4 y 12 kg | B-ALL | 100 mg Oral | NA | CsA g | 7 | 1.79 | YES | 74 | 0.88 | NA | 100 | partial | complete | 59 | 35 | 22 |
| Probable Asp b fumigatus | M 9.1 y 37 kg | Fanconi anemia | 200 mg Oral | NA | CsA g | 5 | 3.87 | NO | 15 | 3.72 | NA | 200 | partial | partial | 98 | 79 | 56 |
| Probable Asp b fumigatus | M 11.2 y 30 kg | Burkitt ALL | 200 mg IV | NA | NA | 4 | 3.29 | NO | 95 | 4.76 | NA | 200 | stable | complete | 399 | 394 | 46 |
| Probable Asp b fumigatus | M 9.1 y 29 kg | B-ALL | 100 mg Oral | NA | NA | 5 | 4.2 | NO | 65 | 5.00 | NA | 100 | partial | complete | 258 | 234 | 35 |
| Probable Asp b fumigatus | F 5.3 y 15 kg | MDS d | 100 mg IV | CASP f | venetoclax/CsA g | 3 | 5.12 | NO | 81 | 3.19 | Increased, 2 times | 140 | partial | partial | 18 | 7 | 30 |
| Prophylaxis | F 4.6 y 18 kg | AML | 100 mg IV | NA | sorafenib/CsA g | 2 | 3.8 | YES | 240 | 2.77 | NA | 100 | NA | NA | 64 | 72 | 30 |
| Prophylaxis | M 15.3 y 48 kg | Fanconi anemia | 200 mg Oral | NA | CsA g | NA | NA | NO | 253 | NA | NA | 200 | NA | NA | 108 | 105 | 50 |
| Prophylaxis | M 15.6 y 58 kg | T-ALL | 200 mg Oral | NA | CsA g | 7 | 4.7 | NO | 119 | 2.95 | NA | 200 | NA | NA | 43 | 92 | 79 |
| Prophylaxis | M 10.1 y 35 kg | Aplastic anemia | 200 mg IV | NA | CsA g | 4 | 2.51 | NO | 183 | 2.93 | Decreased, 2 times/increased 1 time | 100 | NA | NA | 19 | 54 | 51 |
| Prophylaxis | F 14.5 y 61 kg | Aplastic anemia | 200 mg Oral | NA | CsA g | 2 | 3.35 | NO | 109 | 3.29 | NA | 200 | NA | NA | 53 | 114 | 40 |
| Prophylaxis | M 8.1 y 25 kg | B-ALL | 100 mg Oral | NA | CsA g | 3 | 3.51 | NO | 15 | 2.81 | NA | 100 | NA | NA | 20 | 12 | 15 |
a: Mucormycosis, b: Aspergillosis; F: Female; M: Male; c: Anaplastic Large Cell Lymphoma; d: Myelodysplastic Syndrome; e: Liposomal Amphotericin B; f: Caspofungin; g: Cyclosporine; h: Serum Creatinine; NA: Not Applicable.